Securities Report – 44th Fiscal Period (2025/04/01 – 2026/03/31)

Kessho Seibutsu Kenkyusho Co., Ltd. Securities Report – 44th Fiscal Period (2025/04/01 – 2026/03/31)

This document is the securities report submitted by Kessho Seibutsu Kenkyusho Co., Ltd. (hereinafter referred to as "the Company") pursuant to Article 24 of the Financial Instruments and Exchange Act. The Company is listed on the Prime Market of the Tokyo Stock Exchange and is required to timely and appropriately disclose information regarding its financial performance, financial position, and management policies to investors and other stakeholders.

Since its establishment in 1950, the Company has primarily engaged in the research, development, manufacturing, and sales of pharmaceuticals and vaccines based on immunological science. In particular, it has contributed to maintaining public health in Japan through the stable supply of seasonal influenza vaccines and novel coronavirus vaccines. Going forward, the Company intends to focus on developing innovative therapies for cancer immunotherapy and allergic diseases to address unmet medical needs.

Regarding the business environment for the 44th fiscal period, the domestic and international pharmaceutical markets are expected to continue growing, driven by increasing interest in preventive medicine and the aging population. However, challenges such as rising R&D costs, stricter regulations, and intensified global competition remain. Under these conditions, the Company has identified strengthening R&D capabilities, improving production efficiency, and advancing global expansion as key management priorities.

In terms of financial condition, the Company maintains a stable revenue base and is enhancing its financial strength through prudent management of interest-bearing debt. Additionally, through increased retained earnings, the Company is securing financial flexibility to support future investments. The Company will continue to balance shareholder returns with strategic investments aimed at achieving sustainable growth.

This report contains detailed information on the Company's financial position, operating results, and cash flow. It also discloses forward-looking statements regarding future performance and associated risk factors. Investors are advised to review this information carefully and make investment decisions based on their own judgment.

Please note that the contents of this report are based on the Company's current understanding and forecasts as of the filing date, and actual results may vary due to various factors. For detailed financial figures and explanatory notes, please refer to the attached financial statements and accompanying notes.